Canada is “urgently exploring options” with provinces and the energy industry to boost oil supply, as trade disruptions caused by war in the Middle East spur huge volatility in global crude markets https://t.co/IFQaUgJ5yS ...

Core Viewpoint - Utah Medical Products, Inc. (UTMD) reported a disappointing third quarter for 2025, with significant declines in earnings and revenue, attributed to unexpected order cancellations and a challenging operating environment [1][2][5]. Financial Performance - Earnings per share (EPS) for Q3 2025 was 82 cents, down 19.9% from $1.025 in the same quarter last year [1]. - Revenue decreased by 1.9% to $9.8 million from $10 million year-over-year [2]. - Net income fell by 26.2% to $2.6 million from $3.6 million [2]. Key Business Metrics - Gross profit declined 3.4% year-over-year to $5.6 million, with gross margin dropping to 57.1% from 58% [3]. - Operating income decreased by 21.9% to $2.6 million, resulting in an operating margin of 26.6%, down from 33.4% [3]. - Adjusted EBITDA fell 15.9% to $4.2 million, with the adjusted EBITDA margin contracting to 42.5% from 49.6% [4]. Management Commentary - Management cited unexpected cancellations or delays from two non-U.S. distributors, leading to a revenue loss of $0.6 million and a $0.4 million bad debt provision [5]. - The cancellation from a China distributor may indicate the end of a long-term business relationship [5]. - Sales from former major OEM customer PendoTECH dropped to $0.01 million from $0.3 million year-over-year, but management believes this decline has nearly bottomed out [6]. Factors Influencing Results - Manufacturing costs increased due to U.S. tariffs, impacting the cost of goods sold by $0.08 million in Q3 [7]. - Gross margins were further affected by under-absorption of fixed overheads due to lower sales volumes [7]. - Litigation expenses were high at $0.38 million, though down from $0.43 million a year earlier [8]. Revenue Breakdown - Domestic U.S. sales rose 3% year-over-year, driven by a 7.7% increase in direct device sales and a 16.5% gain in Filshie product sales [9]. - International sales declined by 8.5%, significantly impacted by a 21.7% drop in constant currency OUS sales [9]. Guidance - Management now expects full-year 2025 revenue to decline approximately 7% year-over-year, revised from an earlier estimate of a 5% drop [11]. - Adjusted EBITDA for the full year is projected to be in the range of $17 to $18 million [11]. Other Developments - During the quarter, UTMD repurchased 11,729 shares for $0.7 million, totaling 130,984 shares worth $7.4 million year-to-date [12]. - Dividends paid during the quarter amounted to $1 million, representing 38% of quarterly net income [12]. - Since the end of 2023, UTMD has spent $34.6 million on share repurchases and dividends, with a minimal decrease of $8.6 million in cash and investments, indicating strong cash generation capacity [12].